Tekla Capital Management LLC has filed its 13F form on August 10, 2023 for Q2 2023 where it was disclosed a total value porftolio of $2.53 Billion distributed in 166 stocks.

Among their holdings, we can observe that their the top five positions include companies like: Amgen Inc with a value of $137M, Johnson & Johnson with a value of $119M, Gilead Sciences, Inc. with a value of $118M, Regeneron Pharmaceuticals, Inc. with a value of $116M, and Vertex Pharmaceuticals Inc with a value of $112M.

Examining the 13F form we can see an decrease of $79.5M in the current position value, from $2.61B to 2.53B.

Below you can find more details about Tekla Capital Management LLC portfolio as well as his latest detailed transactions.

Portfolio value $2.53 Billion
Healthcare: $2.45 Billion
Real Estate: $50.9 Million
ETFs: $15.4 Million
Basic Materials: $9.44 Million

Stock Holdings Table Market Cap. of Under $50 Millions

Stock Market Cap. Holding Value (Reported) # of Shares. Last Trade Trade History

Summary

  • Portfolio
  • No. of Stocks 166
  • Current Value $2.53 Billion
  • Prior Value $2.61 Billion
  • Filing
  • Period Q2 2023
  • Filing Date August 10, 2023
  • Form Type 13F-HR
  • Activity in Q2 2023
  • New Purchases 9 stocks
  • Additional Purchases 28 stocks
  • Sold out of 0 stocks
  • Reduced holdings in 31 stocks
Track This Portfolio

Track Tekla Capital Management LLC Portfolio

Follow Tekla Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tekla Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Tekla Capital Management LLC with notifications on news.